Literature DB >> 24118509

Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice.

David S O'Tousa1, Kaitlin T Warnock, Liana M Matson, Ojas A Namjoshi, Michael Van Linn, Veera Venkata Tiruveedhula, Meredith E Halcomb, James Cook, Nicholas J Grahame, Harry L June.   

Abstract

Approximately 30% of current drinkers in the United States drink excessively, and are referred to as problem/hazardous drinkers. These individuals, who may not meet criteria for alcohol abuse or dependence, comprise binge, heavy drinkers, or both. Given their high prevalence, interventions that reduce the risk of binge and heavy drinking have important public health implications. Impulsivity has been repeatedly associated with excessive drinking in the clinical literature. As impulsivity is correlated with, and may play a critical role in, the initiation and maintenance of excessive drinking, this behavior may be an important target for therapeutic intervention. Hence, a better understanding of pharmacological treatments capable of attenuating excessive drinking and impulsivity may markedly improve clinical outcomes. The high-alcohol-preferring (HAP) mice represent a strong rodent model to study the relationship between impulsivity and excessive alcohol drinking, as recent evidence indicates they consume high levels of alcohol throughout their active cycle and are innately impulsive. Using this model, the present study demonstrates that the triple monoamine uptake inhibitors (TUIs) amitifadine and DOV 102, 677 effectively attenuate binge drinking, heavy drinking assessed via a 24-hour free-choice assay, and impulsivity measured by the delay discounting procedure. In contrast, 3-PBC, a GABA-A α1 preferring ligand with mixed agonist-antagonist properties, attenuates excessive drinking without affecting impulsivity. These findings suggest that in HAP mice, monoamine pathways may predominate as a common mechanism underlying impulsivity and excessive drinking, while the GABAergic system may be more salient in regulating excessive drinking. We further propose that TUIs such as amitifadine and DOV 102, 677 may be used to treat the co-occurrence of impulsivity and excessive drinking.
© 2013 Society for the Study of Addiction.

Entities:  

Keywords:  Alcohol use disorders; HAP mice; delay discounting; impulsivity; triple uptake inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24118509      PMCID: PMC3984927          DOI: 10.1111/adb.12100

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  52 in total

1.  Delay discounting of money and alcohol in actively using alcoholics, currently abstinent alcoholics, and controls.

Authors:  N M Petry
Journal:  Psychopharmacology (Berl)       Date:  2001-03       Impact factor: 4.530

Review 2.  5-HT receptor regulation of neurotransmitter release.

Authors:  Klaus B Fink; Manfred Göthert
Journal:  Pharmacol Rev       Date:  2007-12       Impact factor: 25.468

3.  Affect-related behaviors in mice selectively bred for high and low voluntary alcohol consumption.

Authors:  Adem Can; Nicholas J Grahame; Todd D Gould
Journal:  Behav Genet       Date:  2011-10-12       Impact factor: 2.805

4.  Neuropsychological function and delay discounting in methamphetamine-dependent individuals.

Authors:  William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

Review 5.  Understanding the construct of impulsivity and its relationship to alcohol use disorders.

Authors:  Danielle M Dick; Gregory Smith; Peter Olausson; Suzanne H Mitchell; Robert F Leeman; Stephanie S O'Malley; Kenneth Sher
Journal:  Addict Biol       Date:  2010-04       Impact factor: 4.280

6.  Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.

Authors:  Andrew R S T Yang; Heon S Yi; Kaitlin T Warnock; Jacek Mamczarz; Harry L June; Nikhil Mallick; Philip A Krieter; Leonardo Tonelli; Phil Skolnick; Anthony S Basile; Harry L June
Journal:  Alcohol Clin Exp Res       Date:  2011-12-07       Impact factor: 3.455

Review 7.  Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents.

Authors:  W J McBride; T K Li
Journal:  Crit Rev Neurobiol       Date:  1998

8.  Dopamine and benzodiazepine-dependent mechanisms regulate the EtOH-enhanced locomotor stimulation in the GABAA alpha1 subunit null mutant mice.

Authors:  Harry L June; Katrina L Foster; William J A Eiler; Joshua Goergen; Jason B Cook; Nathan Johnson; Boikai Mensah-Zoe; Jothan O Simmons; Harry L June; Wenyuan Yin; James M Cook; Gregg E Homanics
Journal:  Neuropsychopharmacology       Date:  2006-05-17       Impact factor: 7.853

9.  Binge drinking among US adults.

Authors:  Timothy S Naimi; Robert D Brewer; Ali Mokdad; Clark Denny; Mary K Serdula; James S Marks
Journal:  JAMA       Date:  2003-01-01       Impact factor: 56.272

10.  A population-specific HTR2B stop codon predisposes to severe impulsivity.

Authors:  Laura Bevilacqua; Stéphane Doly; Jaakko Kaprio; Qiaoping Yuan; Roope Tikkanen; Tiina Paunio; Zhifeng Zhou; Juho Wedenoja; Luc Maroteaux; Silvina Diaz; Arnaud Belmer; Colin A Hodgkinson; Liliana Dell'osso; Jaana Suvisaari; Emil Coccaro; Richard J Rose; Leena Peltonen; Matti Virkkunen; David Goldman
Journal:  Nature       Date:  2010-12-23       Impact factor: 49.962

View more
  5 in total

Review 1.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

2.  Prolonging the Reduction of Nicotine Self-Administration in Rats by Coadministering Chronic Nicotine With Amitifadine, a Triple Monoamine Reuptake Inhibitor With CYP2B6 Inhibitory Actions.

Authors:  Edward D Levin; Corinne Wells; Susan Slade; Michelle Lee; Anthony A McKinney; Jed E Rose; Amir H Rezvani
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

3.  Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption.

Authors:  Chelsea R Kasten; Shelby N Blasingame; Stephen L Boehm
Journal:  Alcohol       Date:  2014-12-17       Impact factor: 2.405

4.  Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.

Authors:  Sarah E Maggio; Meredith A Saunders; Thomas A Baxter; Kimberly Nixon; Mark A Prendergast; Guangrong Zheng; Peter Crooks; Linda P Dwoskin; Rachel D Slack; Amy H Newman; Richard L Bell; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2018-02-18       Impact factor: 4.530

5.  Synthesis of aza and carbocyclic β-carbolines for the treatment of alcohol abuse. Regiospecific solution to the problem of 3,6-disubstituted β- and aza-β-carboline specificity.

Authors:  V V N Phani Babu Tiruveedhula; Kashi Reddy Methuku; Jeffrey R Deschamps; James M Cook
Journal:  Org Biomol Chem       Date:  2015-11-21       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.